This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mizuuchi, H. Articles by Garrett, C. T. Search for Related Content PubMed PubMed Citation Articles by Mizuuchi, H. Articles by Garrett, C. T.

Clinical Implications of K-ras Mutations in Malignant Epithelial Tumors of the Endometrium¹

Departments of Pathology [S. N., S. G. S., C. T. G.] and Statistics/Computer and Information Systems [S. G.], The George Washington University, Washington, DC 20037, and Department of Obstetrics and Gynecology, Sapporo Medical College, W-16 S-1, Chuo-ku, Sapporo, Hokkaido, Japan [H. M., R. K.]

Tumorigenesis in humans and experimental animals appears to involve the activation of ras protooncogenes for a number of organ systems and seems to be important to the development of the metastatic phenotype in several model systems. Clinically, the presence of activated ras protooncogenes has been reported to be a negative prognostic factor in the myelodysplastic syndrome and in adenocarcinoma of the lung. In the present study we examined 49 cases of endometrial carcinoma for mutations in the first exon of K-ras using the polymerase chain reaction and direct sequencing. Mutations in codon 12 or 13 of K-ras were detected in 6 of 49 cases (12.2%). These six cases consisted of five endometrioid endometrial carcinomas, each of which had a mutation in codon 12, and one case of clear cell carcinoma, which had a mutation in codon 13. In our study the presence of mutations in K-ras appeared to be an unfavorable prognostic factor. Three of six patients with the mutation died during follow-up, while only 7% of the 43 patients without K-ras mutations expired during this same period. In multivariate analysis using the Cox proportional hazard model, K-ras activation appeared to be an independent risk factor when compared with clinical stage, depth of myometrial invasion, and patient age. Thus, our findings support the hypothesis that K-ras protooncogene activation plays an important role in determining the aggressiveness of endometrial carcinoma.

¹ Supported in part by Grant R01 CA47994 from the National Cancer Institute, NIH.

² To whom requests for reprints should be addressed, at Department of Pathology, The George Washington University Medical Center, 2300 Eye Street NW, Washington, DC 20037.

Received 10/18/91. Accepted 3/10/92.

This article has been cited by other articles:

				J. Pijnenborg, G. Dam-de Veen, N Kisters, B Delvoux, M van Engeland, J. Herman, and P. Groothuis RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer Ann. Onc., March 1, 2007; 18(3): 491 - 497. [Abstract] [Full Text] [PDF]